Cingulate Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.535
- Today's High:
- $0.6101
- Open Price:
- $0.5452
- 52W Low:
- $0.664
- 52W High:
- $2
- Prev. Close:
- $0.573
- Volume:
- 258972
Company Statistics
- Market Cap.:
- $11.70 million
- Book Value:
- 0.007
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-8995280
- Profit Margin:
- 0%
- Return on Assets TTM:
- -79.81%
- Return on Equity TTM:
- -207.17%
Company Profile
Cingulate Inc had its IPO on 2021-12-08 under the ticker symbol CING.
The company operates in the Healthcare sector and Biotechnology industry. Cingulate Inc has a staff strength of 15 employees.
Stock update
Shares of Cingulate Inc opened at $0.55 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.54 - $0.61, and closed at $0.61.
This is a +6.47% increase from the previous day's closing price.
A total volume of 258,972 shares were traded at the close of the day’s session.
In the last one week, shares of Cingulate Inc have slipped by -4.67%.
Cingulate Inc's Key Ratios
Cingulate Inc has a market cap of $11.70 million, indicating a price to book ratio of 1.2354 and a price to sales ratio of 0.
In the last 12-months Cingulate Inc’s revenue was $0 with a gross profit of $-8995280 and an EBITDA of $-15949158. The EBITDA ratio measures Cingulate Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cingulate Inc’s operating margin was 0% while its return on assets stood at -79.81% with a return of equity of -207.17%.
In Q1, Cingulate Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cingulate Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cingulate Inc’s profitability.
Cingulate Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.4476. Its price to sales ratio in the trailing 12-months stood at 0.
Cingulate Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $7.16 million
- Total Liabilities
- $6.66 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $37135
- Dividend Payout Ratio
- 0%
Cingulate Inc ended 2024 with $7.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.16 million while shareholder equity stood at $81614.00.
Cingulate Inc ended 2024 with $0 in deferred long-term liabilities, $6.66 million in other current liabilities, 1131.00 in common stock, $-73413383.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.74 million and cash and short-term investments were $1.74 million. The company’s total short-term debt was $5,360,326 while long-term debt stood at $0.
Cingulate Inc’s total current assets stands at $3.75 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $31953.00 compared to accounts payable of $599033.00 and inventory worth $0.
In 2024, Cingulate Inc's operating cash flow was $0 while its capital expenditure stood at $37135.
Comparatively, Cingulate Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.61
- 52-Week High
- $2
- 52-Week Low
- $0.664
- Analyst Target Price
- $5.88
Cingulate Inc stock is currently trading at $0.61 per share. It touched a 52-week high of $2 and a 52-week low of $2. Analysts tracking the stock have a 12-month average target price of $5.88.
Its 50-day moving average was $0.67 and 200-day moving average was $0.94 The short ratio stood at 4.33 indicating a short percent outstanding of 0%.
Around 2800.7% of the company’s stock are held by insiders while 208.1% are held by institutions.
Frequently Asked Questions About Cingulate Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company’s lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.